Anesta Corporation

Anesta of Salt Lake City is a leader in the development of new pharmaceutical products for oral transmucosal drug administration. The company's principal product is Actiqr (oral transmucosal fentanyl citrate), which was launched on March 31, 1999. Actiq is marketed and manufactured by Abbott Laboratories in the U.S. under a license agreement with Anesta. Actiq is the first product specifically designed, studied and approved for breakthrough cancer pain. Actiq is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The company has five investigational products in clinical development; OT-nicotine for smoking cessation, OT-fentanyl for acute pain management, OT-etomidate for short-acting sedation, OT-piroxicam as a non-opioid analgesic, and OT-droperidol as an anti-emetic.

Previous Forums
Date/Time		Forum
Nov 20 1999		Second Bay Area Drug Delivery Stocks Forum
Mar 13 1999		Fourth San Diego Biotech Stocks Forum
Mar 13 1999		Sixth Bay Area Biotech Stocks Forum - Foster City, CA
Nov 21 1998		Bay Area Drug Delivery Stocks Forum - Berkley, CA
Apr 18 1998		Utah Growth Stock Forum - Salt Lake City, UT
Mar 14 1998		Second San Diego Biotechnology Forum

Market Assistant		PrecisionAlert
This company has no data		Enter your email address to receive alerts about this company